Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-GPC3 chimeric antigen receptor T cell therapy - Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine

Next Previous
X
Search
Drug Profile

Anti-GPC3 chimeric antigen receptor T cell therapy - Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine

Alternative Names: Anti-GPC3 CAR-T cells; Anti-GPC3 chimeric antigen receptor T cell therapy - Guangdong Zhaotai InVivo Biomedicine/Hunan Yongren Medical Innovation; CAR-GPC3-T-cells; Glypican-3- chimeric-antigen-receptor-T-cell-therapy - Hunan Yongren Medical Innovation; GPC3-CAR-T cell therapy - Hunan Yongren Medical Innovation; GPC3-T2-CAR-T cell therapy

Latest Information Update: 17 Nov 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangdong Zhaotai InVivo Biomedicine; Hunan Yongren Medical Innovation
  • Developer Hunan Yongren Medical Innovation
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Liver cancer; Lung cancer

Most Recent Events

  • 28 Aug 2020 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease) in China (Parenteral)
  • 28 Aug 2020 No recent reports of development identified for phase-I development in Lung-cancer(Late-stage disease) in China (Parenteral)
  • 01 Jul 2017 Phase-I clinical trials in Lung cancer (Late-stage disease) in China (Parenteral) (NCT03198546)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top